



Proteomics International
LABORATORIES LTD

ASX/Media Release

5 March 2018

ASX code: PIQ

Proteomics International completes investment in CPR Pharma Services

Proteomics International Laboratories Ltd (Proteomics International, ASX: PIQ) is pleased to provide an update on the strategic alliance and investment in CPR Pharma Services Pty Ltd (CPR) announced to the market on 2 February 2018.

Pursuant to the Memorandum of Understanding with CPR, and following approval from CPR shareholders, Proteomics International has today issued 3,868,305 fully paid ordinary PIQ shares to acquire 10% of the fully diluted issued share capital of CPR. Based on the 30 day VWAP of \$0.3045 per share, the stake is valued at \$1.2 million. A voluntary escrow period of 12 months applies to the Shares.

The share swap serves to cement a partnership agreement which sees Proteomics International provide its predictive diagnostics and analytical services capability to complement CPR's position as a regional leader in provision of clinical services and laboratory testing in clinical trials [ASX 2 February and 7 February 2018]. The global clinical trials market is projected to reach \$22 billion by 2021.

ENDS

About CPR Pharma Services (CPR) (www.cprservices.com.au)

CPR is a privately owned full service Contract Research Organisation (CRO) specialising in provision of clinical services and laboratory testing in early phase clinical trials. CPR is based in Adelaide and has been providing its services for over 10 years. CPR has over 80 highly skilled technical and operational staff across clinical, data management and laboratory services.

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the art facilities located on the QEII Medical Campus in Perth, Western Australia. The Company's business model uses its proprietary technology platform across three integrated areas of diagnostics, drug discovery and analytical services.

For further information please contact:

Dr Richard Lipscombe
Managing Director
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com
www.proteomicsinternational.com

Paul Hart [Investor Relations]
Director
Canary Capital
T: +61 421 051 474
E: phart@canarycapital.com.au

Susan Fitzpatrick-Napier [Media Contact]
Digital Mantra Group
T: +61 2 8218 2144
E: team@dmgpr.com

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com